Hill Hodgepodge: Pelosi Draws From Democrats, GOP And Trump For Drug Plan
The House speaker announced her plan for lowering drug prices, which includes negotiations between drugmakers and federal health officials.
Drug Costs
321 - 340 of 698 Results
-
-
KHN鈥檚 鈥榃hat The Health?鈥: Tennessee Seeks Medicaid Changes
Tennessee wants to convert its Medicaid program to a block grant. But is its plan legal? Meanwhile, Congress continues to struggle with legislation to rein in prescription drug prices and surprise medical bills. This week, Anna Edney of Bloomberg News, Jennifer Haberkorn of the Los Angeles Times and Kimberly Leonard of the Washington Examiner join KHN鈥檚 Julie Rovner to discuss these issues and more. Rovner also interviews Dr. Marty Makary, author of the new book 鈥淭he Price We Pay鈥 about why health care costs so much.
-
Purveyors Of Black-Market Pharmaceuticals Target Immigrants
Illegal medications, sold in immigrant communities around the United States, can cause serious harm to consumers, authorities say. Law enforcement officers are cracking down, but some think more must be done.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
-
KHN鈥檚 鈥榃hat The Health?鈥: Despite Booming Economy, Uninsured Rate Ticks Up
Nearly 2 million more Americans were uninsured in 2018 than in the previous year, according to the Census Bureau鈥檚 annual report. Plus, the Trump administration announced plans to ban flavored vape liquids, and Congress is back and working to address high prescription drug prices and 鈥渟urprise鈥 medical bills. This week, Joanne Kenen of Politico, Tami Luhby of CNN and Rebecca Adams of CQ Roll Call join KHN鈥檚 Julie Rovner to discuss these issues and more.
-
Legislation To End Surprise Medical Bills Has High Public Support 鈥 In Both Parties
Almost 80% of Americans support efforts in Congress to protect patients from bills that come from doctors or hospitals that were outside their insurance network.
-
States Pass Record Number Of Laws To Reel In Drug Prices
So far this year, 33 states have enacted more than 50 measures to address drug prices, affordability and access. Congress is eyeing the efforts to see what works.
-
Listen: India Gives Opioid Makers A Huge And Growing New Market
KHN's Sarah Varney discussed opioid painkillers in India with NPR's Rachel Martin on "Morning Edition" Thursday.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
-
Shopping At The Apotheke: Compare German Pharmacies With Your Corner Drugstore
Germany鈥檚 pharmacies provide insights into the country鈥檚 low drug prices and strict regulations. But they鈥檙e still businesses.
-
In India鈥檚 Slums, 鈥楶ainkillers Are Part Of The Daily Routine鈥
As the Indian government reluctantly loosens its prescription opioid laws after decades of lobbying by palliative care advocates desperate to ease their patients鈥 pain, the nation鈥檚 sprawling, cash-fed health care system is ripe for misuse.
By Sarah Varney -
Beset By Lawsuits And Criticism In U.S., Opioid Makers Eye New Market In India
What began in India as a populist movement to bring inexpensive morphine to the diseased and dying poor has paved the way for a booming pain management industry. Now, new customers are being funneled to U.S. drugmakers bedeviled by a government crackdown back home.
By Sarah Varney -
Pharma Cash Rolls Into Congress To Defend An Embattled Industry
Congress has a variety of reforms in mind that could roil the drugmaking business and potentially slash prices.
-
Addiction Clinics Market Pricey, Unproven Treatments To Desperate Patients
An amino acid infusion called NAD is not approved by the FDA to treat addiction. Yet patients with addiction can be desperate enough to try it, at prices as high as $15,000.
-
Readers And Tweeters Take Dialysis Providers To Task: Nowhere But In The USA
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
-
KHN鈥檚 鈥榃hat The Health?鈥: All About Medicare
Before 鈥淢edicare for All,鈥 there was just Medicare, the federal program that provides insurance to 60 million Americans. This week, KHN鈥檚 Julie Rovner talks to Tricia Neuman of the Kaiser Family Foundation about how Medicare works and whom it serves. Then, Joanne Kenen of Politico, Paige Winfield Cunningham of The Washington Post and Kimberly Leonard of the Washington Examiner join Rovner to talk about some current Medicare issues being debated in Washington, D.C.
-
Shopping Abroad For Cheaper Medication? Here鈥檚 What You Need To Know
Americans routinely skirt federal law by crossing into Canada and Mexico or tapping online pharmacies abroad to purchase prescription medications at a fraction of the price they would pay at home. Is it safe? Not necessarily. Here鈥檚 some advice.
-
KHN鈥檚 鈥榃hat The Health?鈥: We Answer Your Questions
You asked about drug prices, the 鈥淐adillac tax鈥 on generous insurance plans and why Americans don鈥檛 know that most other countries also have combination public-private insurance systems. This week, Anna Edney of Bloomberg News, Alice Miranda Ollstein of Politico and Caitlin Owens of Axios join KHN鈥檚 Julie Rovner to answer those questions.
-
KHN鈥檚 鈥榃hat The Health?鈥: Gun Violence And The Politics Of Public Health
The recent tragic mass shootings have refocused efforts to treat gun violence as a public health issue rather than strictly a law enforcement problem. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Mary Agnes Carey of Kaiser Health News join KHN鈥檚 Julie Rovner to discuss this, plus the health implications of the budget deal passed by Congress and signed by President Donald Trump, as well as reaction from Canada to a proposal to allow broader imports of its prescription drugs. Plus, for 鈥渆xtra credit,鈥 the panelists recommend their favorite health stories of the week.
-
Drugmakers Master Rolling Out Their Own Generics To Stifle Competition
Known as 鈥渁uthorized generics,鈥 in-house spinoffs of brand-name drugs quietly undermine the competition.
By Jay Hancock and Sydney Lupkin